FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by […]
OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by […]
Video Transcript: Risk-Based Care: Personalized care for better patient outcomes
Risk-Based Care: Personalized care for better patient outcomes Daniel Weaver, BSN, RN, Director, Clinical Innovation and Strategy, Biologics by McKesson: When […]
Video Transcript: Risk-Based Care: Personalized care for better outcomes | Dan & Porscha
Risk-Based Care: Personalized care for better outcomes | Dan & Porscha Daniel Weaver, BSN, RN, Director, Clinical Innovation and Strategy, […]
VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was […]
Improving Oncology Patient Outcomes: The Future of Risk-Based Care
Research shows that Biologics by McKesson’s pioneering risk-based care program maximizes patients’ time on therapy, leading to better oncology patient outcomes.
Video Transcript: Patient Spotlight – Dan W. and Nurse Porscha Scales
Biologics by McKesson Patient Voice Spotlight – Dan W. Yvonne Sims, Senior Manager, Marketing, Biologics by McKesson: So take us to […]
Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich’s Ataxia
CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was […]
JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson
CARY, N.C., Feb. 14, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Feb. 10, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]